Sustained Virologic Response in Hepatitis C Treatment May be Similar for Patients Who Drink Alcohol and Those Who Abstain
Alcohol use hastens the progression of liver disease among individuals with chronic Hepatitis C (HCV) infection, but the impact of ongoing alcohol use on efficacy of HCV treatment is unknown. This retrospective analysis of the Swiss Hepatitis C Cohort assessed alcohol use among 554 patients receiving antiviral therapy for hepatitis C. Participants were divided into 3 groups: nondrinkers (81%), those who consumed 1–24 g per day (15%), and those who consumed >24 g (about 2 drinks) per day (1%). Multivariable analyses included HCV genotype, age, body mass index, cirrhosis, medication type, treatment adherence, and drinking level during treatment. The main outcome was a sustained virologic response (SVR) 6 months following treatment.
- Overall, 58% of participants were adherent to antiviral therapy, and 60% achieved SVR.
- The odds of achieving SVR were lower but not significantly so for those consuming 1–24 g per day (odds ratio [OR], 0.50 and those consuming >24 g per day (OR, 0.7) compared with nondrinkers.